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Abstract
Background:  Several genetic alterations have been demonstrated to contribute to the development and
progression of melanoma. In this study, we further investigated the impact of key-regulator genes in susceptibility
and pathogenesis of such a disease.
Methods: A large series (N = 846) of sporadic and familial cases originating from South Italy was screened for
germline mutations in p16CDKN2A, BRCA2, and MC1R genes by DHPLC analysis and automated DNA sequencing.
Paired primary melanomas and lymph node metastases from same patients (N = 35) as well as melanoma cell lines
(N = 18) were analyzed for somatic mutations in NRAS, BRAF, and p16CDKN2A genes.
Results: For melanoma susceptibility, investigations at germline level indicated that p16CDKN2A was exclusively
mutated in 16/545 (2.9%) non-Sardinian patients, whereas BRCA2 germline mutations were observed in 4/91
(4.4%) patients from North Sardinia only. Two MC1R  germline variants, Arg151Cys and Asp294His, were
significantly associated with melanoma in Sardinia. Regarding genetic events involved in melanoma pathogenesis
at somatic level, mutually-exclusive mutations of NRAS and BRAF genes were observed at quite same rate (about
two thirds) in cultured and in vivo melanomas (either primary or metastatic lesions). Conversely, p16CDKN2A gene
alterations were observed at increased rates moving from primary to metastatic melanomas and melanoma cell
lines. Activation of the ERK gene product was demonstrated to be consistently induced by a combination of
molecular alterations (NRAS/BRAF mutations and p16CDKN2A silencing).
Conclusion: Our findings further clarified that: a) mutation prevalence in melanoma susceptibility genes may vary
within each specific geographical area; b) multiple molecular events are accumulating during melanomagenesis.
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Background
In fair skinned populations, both incidence and mortality
rates of melanoma have been increasing over the past dec-
ades [1]. Fortunately, the most recent data on the
melanoma epidemic suggest that majority of melanoma
patients presents with thin lesions (Breslow thickness ≤
1.00 mm) at the time of diagnosis, due to a steady
improvement of the secondary prevention and early
detection [2].
Baseline melanoma incidences have been found to vary
according to the population's origin: Australia, the United
States, and Sweden present a higher baseline incidence
than Europe (except Sweden) [3,4]. Considering the Euro-
pean population, there is a gradient of melanoma inci-
dence moving from northern countries (where incidence
is higher) to southern countries [5]. In Italy, different inci-
dence rates of melanoma between the northern and
southern parts of the country (standardized rates per year
per 100.000 inhabitants: 10.5-13.5 in North Italy versus
3.5-4.5 in South Italy) have been also reported [5].
Environmental and, mostly, genetic factors have been
demonstrated to participate in susceptibility and patho-
genesis of human melanoma. An intermittent exposure to
ultraviolet radiation, especially in combination with
endogenous factors like skin type and number of nevi, is
the most commonly involved environmental factor [6-9].
From the genetic point of view, several gene alterations
have been implicated. Germline mutations in p16CDKN2A
gene represent the most recognized cause of inherited
melanoma susceptibility. Prevalence of p16CDKN2A muta-
tions seems to be heterogeneously distributed among
melanoma patients within different geographical areas
[10]; our previous study on melanoma patients originat-
ing from South Italy indicated that p16CDKN2A mutations
were absent in North Sardinia and occurred in non-Sar-
dinian patients only [11]. Several low-penetrance candi-
date genes, such as breast cancer susceptibilitygene 2
(BRCA2) and melanocortin-1-receptor (MC1R), have been
also implicated in melanoma predisposition [12,13].
Inherited mutations of the BRCA2 gene have been associ-
ated to development of both ocular and cutaneous
melanomas, in addition to the main predisposition to
breast and ovarian cancers [12-14]. The MC1R  gene
encodes the melanocyte-stimulating hormone receptor
(MSHR), a member of the G-protein-coupled receptor
superfamily and represents one of the major genes which
determine skin pigmentation [15-17]. The MC1R gene is
remarkably polymorphic in Caucasian populations [18];
its sequence variants can result in partial (r) or complete
(R) loss of the receptor's signalling ability [19]. The MC1R
variants were suggested to be associated with red hair, fair
skin, and increased risk of both melanoma and non-
melanoma skin cancers [18-21]. Moreover, melanomas
developed on skin not chronically exposed to sun usually
carry either a mutated NRAS or mutated BRAF or concur-
rently mutated BRAF and PTEN [22]; evidence indeed sug-
gest that BRAF/PTEN and NRAS somatic mutations are
mutually exclusive or, in other words, that both mutation
subsets does not occur in the same melanoma cell [22-
25]. Finally, the ERK1-2 proteins, which represent the
downstream components of the NRAS-BRAF-MEK signal-
ing kinase cascade, have been found to be activated
through phosphorilation (pERK1-2) in melanoma and
implicated in rapid malignant cell growth, mostly as a
consequence of mutations in upstream components of
the pathway [25-27].
The aim of the present study was to evaluate the spectrum
of such genetic alterations in both germline DNA, using a
clinic-based series of sporadic and familial melanomas
from South Italy (including cases from the entire Sardinia
island), and somatic DNA, using a subset of melanoma
tissues and cell lines. Correlations between genetic altera-
tions and melanoma susceptibility or pathogenesis was
thus inferred.
Methods
Melanoma cases
Eight hundred and forty-six patients with histologically-
proven diagnosis of cutaneous melanoma were included
into the study. Among them, 301 originated from Sar-
dinia and 545 from other southern Italian regions; no
substantial difference was observed in patients' character-
istics between the Sardinian and non-Sardinian series. To
avoid any bias, patients were consecutively collected from
January 2001 to December 2006; they were included
regardless of age of onset, cancer family history, and dis-
ease characteristics. Moreover, 35 melanoma tissues (par-
affin-embedded primary melanomas and frozen samples
from synchronous or asynchronous lymph node metas-
tases of the same patients) and 18 melanoma cell lines
(cultured from primary and metastatic tumours - see
below) were collected.
Clinical and pathological features such as histological
classification (including Breslow thickness) and disease
stage at diagnosis were confirmed by medical records,
review of pathologic material, and/or pathology reports.
Familial recurrence of melanoma was ascertained by using
a questionnaire to interview probands about their first-,
second-, and third-degree relatives. Melanoma families
were identified according to standardized criteria [23]: a)
at least three affected members, or b) two affected mem-
bers and presence of at least one of the following subcrite-
ria: i) at least one affected member younger than 50 years
at onset, or ii) a case of pancreatic cancer in a first- or sec-
ond-degree relative, or iii) one affected member with mul-BMC Cancer 2009, 9:352 http://www.biomedcentral.com/1471-2407/9/352
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tiple primary melanomas. Patients were informed about
aims and limits of the study and blood samples were
obtained with their written consent.
The study was reviewed and approved by the ethical
review boards of both Azienda USL1 and University of
Sassari.
Mutation screening of candidate genes
For mutation analysis, genomic DNA was isolated from
peripheral blood samples or tumour tissues or melanoma
cell lines, using standard methods. At germline DNA level,
the full coding sequences and splice junctions of
p16CDKN2A (exons 1α, 2, and 3) and BRCA2 (exons 1-26)
genes were screened for mutations using denaturing high-
performance liquid chromatography (DHPLC) on a
Wave® nucleic acid fragment analysis system (Transge-
nomic, Santa Clara, CA). As previously reported by our
group[28], abnormal PCR products identified by DHPLC
analysis were directly sequenced using an automated flu-
orescence- cycle sequencer (ABIPRISM 3130, Applied Bio-
systems, Foster City, CA). About half of the present cohort
(437 patients) has been already tested for p16CDKN2A germ-
line mutations in our previous study [11]. Subsets of Sar-
dinian patients originating from all geographical areas
within the island were screened for mutations in the
MC1R gene as above. At somatic DNA level, the full cod-
ing sequences and splice junctions of p16CDKN2A, NRAS
(exons 2-3), and BRAF (exons 2-17) genes were screened
for mutations as above. Primer sets and protocols for
polymerase chain reaction (PCR) assays were as previ-
ously described [11,20,28,29]. For melanoma cell lines,
we also performed mutation analysis of the PTEN gene
(exons 1-9); primer sequences were as reported in
Genome DataBase (GDB at http://www.gdb.org).
To evaluate the prevalence of each gene variant in a con-
trol population, unrelated healthy individuals, originat-
ing from the same geographical areas and with no
recurrence of cancer in family, were used as controls and
screened for sequence variations.
Immunochemical analysis
Immunocytochemistry was performed on cultured
melanoma cells, using standard procedures. Melanoma
cell lines were kindly provided by Dr. Stefania D'Atri at
the Institute Dermopatico dell'Iacolata in Rome. They were
established as primary short term cell cultures starting
from tumour samples of donors patients with docu-
mented diagnosis of melanoma, after obtaining their
informed consent Immunocytochemical analysis was per-
formed using primary monoclonal antibodies against
p16CDKN2A (JC-2 Lab Vision-Neo-Markers, Fremont, CA)
and pERK1-2 (Santa Cruz Biotechnology, Santa Cruz, CA)
proteins.
Immunocytochemical staining was evaluated semi-quan-
titatively, using antibody negative and positive controls.
Intensity and distribution of immunostaining was used to
classify cells as positive (strong [+++] to moderate [++]
staining, homogeneously distributed or presented by
large majority of tumour cells) or negative (absent [-] or
weak staining [+]) for gene expression. Scoring was per-
formed by at least two investigators (in very few border-
line cases, classification of immunostaining required
additional investigators and was based on the consistency
of the majority of them).
Statistical analysis
Statistical correlation between MC1R germline mutations
and disease was performed by chi-square test. Odds ratios
of carrying gene mutations were estimated by the logistic
regression model and are reported with 95% confidence
interval (95% CI). Features for the relative risk calculation
were analyzed as dichotomous variables (presence versus
absence). The exact coefficient for sample proportion
analysis was performed to determine all significant
parameters (below 0.05 level). All analyses were per-
formed using the statistical package SPSS/7.5 per Win-
dows.
Results
Predisposing mutations in melanoma
Genomic DNA from 301 melanoma patients with ascer-
tained Sardinian origin and 545 melanoma cases originat-
ing from non-Sardinian southern Italian regions was
screened for germline mutations of p16CDKN2A, the main
melanoma susceptibility gene. PCR products correspond-
ing to the coding exons and intron-exon junctions were
analyzed for mutations as described in Methods. For
p16CDKN2A gene, 7 germline mutations were detected in
16/545 (2.9%) non-Sardinian patients (Table 1). All
mutations have been reported as disease-related variants
in the Human Gene Mutation Database at http://
archive.uwcm.ac.uk; the S12X and E26X mutations were
classified as disease-causing variants due to their trunca-
tion effect on proteins. In particular, six (17.1%)
p16CDKN2A mutation carriers were among 35 melanoma
patients who had at least one additional affected mem-
bers in the family; the remaining ten (2.0%) p16CDKN2A
mutation carriers were among 510 melanoma patients
with sporadic disease (Table 2). None of 301 Sardinian
patients was found positive for germline mutations in
such a gene (Table 2). All p16CDKN2A  mutations were
absent in normal genomic DNA from 103 unrelated
healthy individuals (corresponding to 206 control chro-
mosomes), originating from the same geographical areas.
The p16CDKN2A remained a melanoma susceptibility gene
for non-Sardinian patients only; its involvement into the
disease was absent among Sardinian patients. Therefore,BMC Cancer 2009, 9:352 http://www.biomedcentral.com/1471-2407/9/352
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we investigated whether additional candidate genes, such
as BRCA2 and MC1R, might play a role in melanoma sus-
ceptibility within such an isolated population. Again,
mutation screening for all coding regions and splice
boundaries of BRCA2 and MC1R genes was performed as
above.
Four (1.3%) out of 301 Sardinian patients were found to
carry germline mutations in coding regions of the BRCA2
gene (three cases with BRCA2-8765delAG and the
remaining one with BRCA2-Ser2835Pro); conversely, no
BRCA2 mutation was observed in a subset of 154 non-Sar-
dinian patients (to avoid any bias, mutation analysis for
BRCA2 gene was performed on first 154 consecutively-
collected cases from South Italy) (Table 2). Interestingly,
all BRCA2 mutations of our series were detected in the
subset of patients originating from North Sardinia (4/91;
4.4%); one BRCA2-positive case was among 4 patients
with familial recurrence of melanoma, whereas the
remaining three (3.4%) BRCA2-positive cases were
among 87 patients with sporadic melanoma (Table 2).
Both BRCA2 mutations were classified as disease-causing
variants due to their predicted effect on proteins; they
have been previously reported into the Breast Cancer
Information Core (BIC) database at http://
research.nhgri.nih.gov/bic/. Again, all BRCA2 mutations
were not detected in normal genomic DNA from 103
unrelated Sardinian healthy individuals (corresponding
to 206 control chromosomes). Cases with either familial
or sporadic melanoma originating from other areas of the
Sardinia island presented no germline mutation in BRCA2
gene (Table 2).
The entire coding region of the MC1R  gene was then
screened for germline sequence variations in 269 Sardin-
ian melanoma patients (32 cases of our series were
excluded because of DNA degradation or low amount of
available genomic DNA) and 102 control subjects who
were chosen as representative of the individuals living in
the same geographical area and comparable for sex, age,
general phenotype, and phototype to melanoma patients.
Overall, 20 different MC1R variants were found; they were
Table 1: Germline mutations in p16CDKN2A and BRCA2 genes.
Gene Nucleotide Codon Base Change Amino Acid Change Designation
P16CDKN2A 35 12 C to A Ser to Stop S12X
P16CDKN2A 71 24 G to C Arg to Pro A24P
P16CDKN2A 76 26 G to T Glu to Stop E26X
P16CDKN2A 106 36 G to A Ala to Thr A36T
P16CDKN2A 176 59 T to G Val to Gly V59G
P16CDKN2A 301 101 G to T Gly to Trp G101W
P16CDKN2A 326 109 C to T Ala to Val A109V
BRCA2 8503 2835 T to C Ser to Pro Ser2835Pro
BRCA2 8765 2845 delAG Stop 2867 8765delAG
Table 2: Distribution of germline mutations in p16CDKN2A and BRCA2 genes according to patients' origin
Analyzed gene
Patients' origin
No. of analyzed patients Positive cases
No. %
CDKN2A 846 16 1.9
non-Sardinian 545 16 2.9
Familial 35 6 17.1
Sporadic 510 10 2.0
Sardinian 301 0
Familial 10 0
Sporadic 291 0
BRCA2 455 4 0.9
non-Sardinian 154 0
Sardinian 301 4 1.3
North Sardinia 91 4 4.4
Familial 4 1 25.0
Sporadic 87 3 3.4
Middle-South Sardinia 210 0
Familial 6 0
Sporadic 204 0BMC Cancer 2009, 9:352 http://www.biomedcentral.com/1471-2407/9/352
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classified according to the effect of the gene sequence var-
iations on the protein function [partial (r) or complete (R)
loss of the receptor's signalling ability, as previously
reported [20] (Table 3). Two MC1R germline variants clas-
sified as "R", Arg151Cys [odds ratio (OR), 6.4; 95% con-
fidence interval (95% CI), 2.1-15.9] and Asp294 His (OR,
1.8; 95% CI, 1.1-5.3), were significantly associated with
melanoma in our series (Table 3). Considering the indi-
viduals who were either homozygous or heterozygous for
the "R" variant of the MC1R gene, the occurrence of such
a "R" allele into the genotype was significantly associated
with melanoma (p = 0.043; OR, 2.3; 95% CI, 1.2-7.8)
(Table 4). No phenotypic parameter in our series of
melanoma patients [sex, age of onset, primary tumour
location, stage of disease, family history of melanoma, or
geographical origin (North vs. Middle-South Sardinia)]
was statistically correlated with the presence of the "R"
genotype in MC1R gene (data not shown).
Pathogenetic alterations in melanoma
A high prevalence of somatic mutations was detected in a
subset of paired primary and secondary (lymph node
metastasis) melanomas from 35 patients of the series
(Table 5). Confirming previously reported data, BRAF and
NRAS mutations were mutually exclusive in our patients'
collection; overall, BRAF  or  NRAS  mutations were
detected in 23/34 (68%) primary tumours and 24/35
(69%) lymph node metastases from the same melanoma
patients (Table 5). With the exception of one BRAF muta-
tion (L597R) occurred in metastatic sample only, no dif-
ference in rates and types of mutations in BRAF and NRAS
genes was observed between primary and secondary
tumour tissues from same patients (Table 5). The rate of
mutations in p16CDKN2A  gene was found to instead
increase from primary to metastatic melanomas of the
same patients [5/33 (15%) to 8/35 (23%), respectively]
(Table 5); in this sense, an even higher prevalence of
p16CDKN2A alterations [8 (44%) gene mutations or hemi-
homozygous exon deletions; 11 (61%) gene down-regu-
lations] was observed in our series of 18 melanoma cell
lines (Table 6). Conversely, a quite similar rate of BRAF-
NRAS  mutations (11/18; 61%) was detected in
melanoma cell lines when compared to the uncultured
melanomas (Table 6). Again, all detected mutations have
been previously reported in the Human Gene Mutation
Database at http://archive.uwcm.ac.uk.
No PTEN mutation was found in melanoma cell lines
Considering the immunocytochemical results, all
melanoma cell lines (7/7; 100%) with concurrent muta-
tion of BRAF-NRAS  and down-regulation of p16CDKN2A
presented high expression levels of the activated pERK1-2
protein (Figure 1). The remaining subsets of melanoma
cell lines with alterations of one or none of such genes
presented lower rates of ERK1-2 phosphorilation [5/8
(62%) and 1/3 (33%), respectively] (Figure 1), suggesting
that coexistence of multiple molecular events may be
required for activating ERK in melanoma. In Figure 2, the
expression of ERK1, ERK2, and pERK1-2 proteins was vali-
dated by Western blot hybridization in M14 and PR-Mel
melanoma cell lines.
Table 3: Distribution of MC1R variants among Sardinian melanomas and controls
MC1R variants Landi's classification Positive cases (N = 269) % Positive controls (N = 102) % P
Val60leu (V60L) R 88 32.7 32 31.4 n.s.
Ser83Pro (S83P) R 3 1.1 1 1.0 n.s.
Asp84Glu (D84E) R 1 0.4 0 0 n.s.
Val92Met (V92M) R 16 5.9 5 4.9 n.s.
Thr95Met (T95M) R 3 1.1 1 1.0 n.s.
Gly104Ser (G104S) R 2 0.7 1 1.0 n.s.
Arg142Cys (R142C) R 1 0.4 0 0 n.s.
Arg142His (R142H) R 9 3.3 3 2.9 n.s.
Arg151Cys (R151C) R 19 7.1 1 1.0  > 0.01
Tyr152Term (Y152Term) R 1 0.4 0 0 n.s.
Ile155Thr (I155T) R 4 1.5 2 2.0 n.s.
Arg160Trp (R160W) R 13 4.8 3 2.9 0.136
Arg163Gln (R163Q) R 7 2.6 2 2.0 n.s.
Ser172Ile (S172I) R 1 0.4 0 0 n.s.
Arg213Trp (R213W) R 5 1.9 1 1.0 n.s.
Ile221Thr (I 221 T) R 1 0.4 0 0 n.s.
Pro256Ser (P256S) R 2 0.7 0 0 n.s.
Asp294His (D294H) R 31 11.5 5 4.9 0.048
Thr308Met (T308M) R 2 0.7 0 0 n.s.
InsA724 R 2 0.7 0 0 n.s.
MC1R variants with complete loss of function are defined as "R" (in bold), whereas variants with partial loss of function are defined as "r". P values 
(chi-squared test; two tailed; 95% confidence interval) were given for MC1R-"R" variants only. n.s., not significantBMC Cancer 2009, 9:352 http://www.biomedcentral.com/1471-2407/9/352
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Discussion
Melanocytic transformation is thought to occur by
sequential accumulation of alterations in several genes
and metabolic pathways [8,30,31]. In our study, we tried
to better define the role of the genes mainly involved in
melanoma susceptibility (through the assessment of the
prevalence of predisposing germline mutations) and
pathogenesis (by investigating somatic gene down- or up-
regulations in tumour tissues and cancer cell lines).
Melanoma susceptibility
Assessment of the prevalence of predisposing germline
mutations in candidate genes represents an important
step toward prevention and early detection of cancers. In
this sense, the mutation analysis of p16CDKN2A, which is
the main gene associated with melanoma susceptibility
[8,30], should be considered as a crucial step. Due to envi-
ronmental and genetic factors, prevalence of p16CDKN2A
mutations has been demonstrated to deeply vary among
different populations [10]. A real estimation of the pro-
portion of positive and negative tests that might be
expected in a referral risk evaluation clinic is therefore fun-
damental to provide clinical recommendations for
p16CDKN2A genetic testing.
Table 4: Frequency of R-containing genotypes in MC1R gene 
among Sardinian melanomas and controls
Positive cases
Subgroups (No. of subjects) No. % P
Patients (269)
R/R or R/r or R/wt genotypes 63 23.4 0.041
Controls (102)
R/R or R/r or R/wt genotypes 9 8.8
Table 5: Somatic mutations in BRAF, NRAS, and p16CDKN2A genes among in vivo melanoma tissues
Case Sex Age at diagnosis Primary tumour Lymph node metastasis
BRAF NRAS p16CDKN2A BRAF NRAS p16CDKN2A
MN01 M 43 L597R
MN02 F 63 Q61R Q61R
MN03 M 51 V600E V600E
MN04 M 40 V600E V600E
MN06 M 49 V600E V600E
MN07 M 39 V600E V600E
MN08 F 65 Q61R Q61R
MN09 M 34 Q61R Q61R
MN10 M 67 V600E Arg24Pro V600E Arg24Pro
MN11 M 84 V600K V600K
MN12 M 74
MN14 M 41 n.t.
MN15 M 63 Arg80ter
MN18 M 75
MN19 M 30 V600E V600E
MN20 F 45 V600E V600E
MN21 M 35 Ala36Thr Ala36Th
MN22 M 71 Q61R Q61R
MN25 F 35 V600E V600E
MN26 M 50 Q61R Q61R
MN27 F 48
MN28 F 58 Q61K Q61K
MN29 M 51 V600E V600E
MN31 M 40 Q61R Q61R
MN34 F 65 Q61R Ala109Val Q61R Ala109Val
MN35 M 61
MN36 M 64 Trp110ter Trp110ter
MN41 F 69
MN45 F 56 n.t. n.t. n.t. Arg80ter
MN05 M 51 V600E V600E IVS1+1G>A
MN55 F 34
MN56 F 36 V600E V600E
MN59 F 53 Q61K Q61K
MN68 M 45 Q61R Q61R
MN75 F 56 Q61R Arg24Pro Q61R Arg24Pro
Primary melanomas are in bold. n.t., not testedBMC Cancer 2009, 9:352 http://www.biomedcentral.com/1471-2407/9/352
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In our analysis, p16CDKN2A  germline mutations were
detected in about 3% (16; 2.9%) out of 545 melanoma
patients from southern Italian regions not including Sar-
dinia; in this island, none of the 301 analyzed patient was
found to carry a p16CDKN2A mutation. When Sardinian
patients were screened for germline mutations in BRCA2
gene, which seems to play a major role in predisposition
to different types of cancer including melanoma
(although data are still insufficient, annual skin and eye
examinations for early diagnosis of melanoma have been
proposed for genetic counselling of BRCA2 carriers) [11-
14], we exclusively observed a mutated BRCA2 gene in
patients originating from North Sardinia (4/91; 4.4%); no
BRCA2 germline mutation was observed in 210 patients
originating from the remaining areas of the island or in a
subset of 154 non-Sardinian melanoma cases (see Table
2). Moreover, we obtained evidence that no sequence var-
iation was present in p15CDKN2B and CDK4, the remaining
two high penetrance melanoma susceptibility genes,
among familial melanoma cases from our southern Ital-
ian population ([32] and unpublished data). Therefore,
the central-southern part of the Sardinia island should be
considered as a geographical area in which melanoma
patients do not carry mutations in any known major sus-
ceptibility gene. Since the incidence rates of melanoma
are quite similar in both Sardinian, genetically homoge-
neous, and non-Sardinian, genetically heterogeneous,
populations from South Italy (roughly, 4 new cases per
100.000 inhabitants per year [5]), our findings seem to
further confirm that genetic factors predisposing to
melanoma are geographically heterogeneous and strictly
depending on patients' origin. On this regard, it is worth
to underline that Sardinia island has a relatively small and
isolated population with a high rate of inbreeding; in
comparison to the genetically-heterogeneous Italian pop-
ulation, a higher prevalence of mutations with founder
effect has been reported (even for cancer diseases)
[33,34]. Nevertheless, one could speculate that prevalence
of mutations in melanoma susceptibility genes needs to
be investigated in every different geographical area.
Considering the familial recurrence of melanoma, 48/846
(5.7%) patients from our series presented at least one
additional affected member in the family. Overall, seven
(14.6%) melanoma families had a detectable mutation in
p16CDKN2A or BRCA2 gene. Also considering some lack of
sensitivity of the mutation analysis approach, the preva-
lence of such germline mutations among patients with
familial melanoma from South Italy remains low. How-
ever, vast majority of the families included into the
present study contains two melanoma patients only;
therefore, more stringent selection criteria or subcriteria
should be used in order to reduce chances that the identi-
fied melanoma families may simply represent a cluster of
sporadic cases. As a confirmation of this hypothesis, a
consistent increase in prevalence rate of p16CDKN2A muta-
tions was observed among families with three affected
members (3/7; 42.9%). Although large genomic deletions
may escape detection by direct sequencing, undetected
mutations are unlikely to explain the high number of fam-
Table 6: Genetic and functional alterations in candidate genes among in vitro melanoma cell lines
Cell line
derived from
ERK1 ERK2 pERK p16 BRAF NRAS p16CDKN2A
Primary melanoma
GR-Mel +++ ++ + ++
LCP-Mel +++ +++ ++ + V600R Del exon 2
MNG +++ +++ ++/+++ +
PNP-Mel +++ +++ ++ + V600E G101W
ST-Mel ++/+++ +++ +++ ++ G466E
Metastatic lymph node
CN-Mel +++ +++ ++ + Q61R
CR-Mel +++ +++ ++ + Q61K Del exon 2
GL-Mel +++ +++ ++ + Del exon 2
LCM-Mel +++ ++ ++ - V600R Del exons 1-2
MAR +++ +/++ + +
SK-Mel-28 +++ ++ ++ +++ V600E
13443-Mel +++ ++ + +++
Cutaneous metastasis
LB-24-Mel +++ +++ +++ ++
M14 +++ +++ ++ + V600E 455insCdel26 IVS1+2T>C
PR-Mel +++ +++ + ++ V600R
SN-Mel ++ ++/+++ + ++ V600E
WM-266-4 +++ ++ ++/+++ - V600D Del exon 1
397-Mel ++ ++ ++ + Del exon 2BMC Cancer 2009, 9:352 http://www.biomedcentral.com/1471-2407/9/352
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ilies without mutations. Therefore, these data further sup-
port the hypothesis that additional low-penetrance
melanoma susceptibility genes remain to be identified.
Finally, our study confirmed the association of some
MC1R  gene variants with the occurrence of cutaneous
melanoma as previously reported [15,35,36]. Despite the
MC1R sequence screening was carried out among Sardin-
ian patients only (due to the availability of control sub-
jects representative of the individuals living in the island
and comparable for phenotypic features to melanoma
patients), the variants classified as "R" and, particularly,
the Arg151Cys and Asp294His alleles appeared to be asso-
ciated with melanoma. Considering the functional out-
come, both Arg151Cys and Asp294His variants have been
demonstrated to affect the normal signalling of the
melanocortin-1 receptor by reducing the ability to elevate
the intracellular levels of cAMP [16]. Further and more
specific studies (based on better classification of the differ-
ent skin phototypes and/or a more detailed evaluation of
the general phenotypic characteristics) are required in
order to define the role of such MC1R gene variants into
the susceptibility to melanoma.
Melanoma pathogenesis
We here examined the relationship between alterations in
NRAS,  BRAF, and p16CDKN2A  genes in both in vivo
melanoma tissues (N = 35) from southern Italian patients
and in vitro melanoma cell lines (N = 18). We found that
mutually exclusive mutations of NRAS and BRAF genes
occur at quite same rate in cultured and uncultured
melanomas (either primary or metastatic lesions), con-
firming that they represent an early event within the cas-
cade of alterations involved into the melanomagenesis.
However, distribution of mutations in each gene (NRAS
or BRAF) deeply varied into the analyzed somatic samples
from our series (see Tables 5 and 6), suggesting that
pathogenetic alterations may indifferently affect kinases
acting either up- or downstream within such a signalling
cascade. Moreover, no concurrent mutation of the PTEN
gene was observed in melanoma cell lines; this is clearly
in contrast with previous data from other series, which
reported that such a gene is mutated at a rate of about
30% among in vitro melanomas [37]. Conversely,
p16CDKN2A  gene mutations and/or rearrangements
(mostly, represented by exon deletions) were observed at
increased rates moving from primary to metastatic
Classification of melanoma cell lines according to alterations in NRAS/BRAF genes and p16CDKN2A/pERK1-2 protein expression Figure 1
Classification of melanoma cell lines according to alterations in NRAS/BRAF genes and p16CDKN2A/pERK1-2 pro-
tein expression. Data regarding occurrence of mutations in BRAF/NRAS genes (mut), down-regulation of p16CDKN2A protein 
(p16-), and over-expression of phosphorilated ERK1-2 protein (pERK1-2+) are indicated. Exemplificative immunochemical results 
are shown.BMC Cancer 2009, 9:352 http://www.biomedcentral.com/1471-2407/9/352
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melanomas and melanoma cell lines (see Tables 5 and 6).
Down-regulation or inactivation of the p16CDKN2A gene (in
our series, about two thirds of melanoma cell lines pre-
sented a reduced or absent expression of the p16CDKN2A
protein) has been demonstrated to affect the control of
cell growth, which may induce cell proliferation and
increase aggressiveness of transformed melanocytic cells
(melanoma cells tend to inactivate both alleles of such a
tumour suppressor gene) [38].
Presence of BRAF mutations in benign and dysplastic nevi
[39] supports the hypothesis that activation of the NRAS-
BRAF-ERK pathway is not sufficient to induce the malig-
nant process and fully transform proliferating melano-
cytes, but requires additional, cooperating de-regulative
events. In our series, the increased activity of ERK1/2 pro-
teins was mainly a consequence of a combination of
mutations in upstream NRAS/BRAF components of the
pathway and silencing of the p16CDKN2A gene (although
additional - and yet unidentified - functional alterations
may participate in inducing such a ERK activation) (see
Figure 1). Therefore, our data provide an additional con-
firmation that multiple molecular events are being accu-
mulated during melanomagenesis.
Identification of the predominant germline mutations in
candidate susceptibility genes within a particular geo-
graphical area has particular relevance to achieve a predic-
tion of the melanoma risk as well as to address patients
and their families to clinical screening. On this regard, a
dramatic improvement toward an earlier diagnosis of
melanoma could be represented by the selection of spe-
cific high-risk groups to be appropriately targeted (since
routine screening for detection of thinner melanoma can
not be indiscriminately proposed). Familial melanoma
patients are reported to present with thinner melanomas
[8]. As also indicated above, different classifications of
familial melanoma have been used by several authors,
based on number (two cases with additional and various
subcriteria or at least three cases) and type (involvement
of first- and/or second-degree relatives) of affected family
members. Regardless the occurrence of a weak or strong
family history, relatives of melanoma patients carrying
germline mutations in susceptibility genes could repre-
sent a high risk group which might undergo a surveillance
program for identification of thinner melanoma. Our
experience seems to support this hypothesis. Considering
the non-Sardinian melanoma patients (whose series was
the only one in which we detected p16CDKN2A germline
mutations), first- and second-degree relatives of
p16CDKN2A mutation carriers were informed to belong to a
putative high risk group (through specific educational ses-
sions, after obtaining an informed consent) and
addressed to a short-term (6 months) surveillance pro-
gram using epiluminescence microscopy. After a median
follow-up of 78 months (range, 37-109), six new melano-
mas with median Breslow thickness of 0.35 mm (range,
0.25-0.68) were observed among such relatives of
p16CDKN2A mutation-positive patients (it is important to
underline that patients with very thin melanomas - Bres-
low thickness ≤ 0.40 mm - present a 10-year survival rate
which is estimated to be more than 98% [40,41]).
Although the number of events for more mature and
definitive results is really low, we could speculate that the
identification of a melanoma patient carrying a p16CDKN2A
germline mutation should induce clinicians to educate his
family members to have a great care of all skin lesions and
pay high attention to noticing any nevi' modification as
well as to address them to a routine screening for detec-
tion of thinner melanoma.
Conclusion
Although most genetic and molecular alterations have
been identified, characterization of all interactions
between key effectors in MAPK, CDKN2A, and additional
(i.e. PTEN-AKT) pathways will represent the aims of
future research efforts, in order to further clarify the
sequence of events inducing transformation of melano-
cytes and progression of melanoma.
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